SeaStar Medical (ICU) has shipped QUELIMMUNE to a California medical center recognized as a world leader in pediatric research and treatments, increasing commercial customers to five. QUELIMMUNE is the company’s Selective Cytopheretic Device, SCD, for treating critically ill children in the intensive care unit, ICU, with acute kidney injury, AKI, and sepsis.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICU:
- SeaStar Medical activates 15th site for adult acute kidney injury trial
- SeaStar Medical Gains FDA Approval for Pediatric Device
- SeaStar Medical says FDA approves feasibility study with SCD-ADULT
- SeaStar Medical begins shipping to QUELIMMUNE
- SeaStar Medical activates 14th hospital for adult AKI trial